```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
 * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:54:02 ON 09 JUL 2010

=> file reg
=>uploading C:\Program Files\Stnexp\Queries\Queries\10572706_species.str
```



```
chain nodes :
7  14  15  16  17  24  26
ring nodes :
1  2  3  4  5  6  8  9  10  11  12  13  18  19  20  21  22  23
chain bonds :
1-11  5-14  6-7  14-15  14-16  16-17  17-20
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-13  9-10  10-11  11-12  12-13  18-19  18-23
19-20  20-21  21-22  22-23
exact/norm bonds :
1-2  1-6  1-11  2-3  3-4  4-5  5-6  6-7  14-15  14-16  16-17
exact bonds :
5-14  17-20
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13  18-19  18-23  19-20  20-21  21-22  22-23
isolated ring systems :
containing 18 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:CLASS  25:Atom  26:Atom  27:Atom

=> s l1 sam
L2            0 SEA SSS SAM L1

=> s l1 full
L3            2 SEA SSS FUL L1

=> file caplus

=> s l3
L4            1 L3

=> dis l4 bib abs hitstr

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2010 ACS on STN
AN   2005:260028  CAPLUS  Full-text
DN   142:316705
```

TI Preparation of 2-pyridone derivatives as neutrophil elastase inhibitors and their use for treating inflammation
IN Andersson, Marjana; Hansen, Peter; Loenn, Hans; Nikitidis, Antonios; Sjoelin, Petter
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026123	A1	20050324	WO 2004-SE1335	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004272484	A1	20050324	AU 2004-272484	20040915
	AU 2004272484	B2	20080313		
	CA 2538405	A1	20050324	CA 2004-2538405	20040915
	EP 1663973	A1	20060607	EP 2004-775438	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014548	A	20061107	BR 2004-14548	20040915
	CN 1882542	A	20061220	CN 2004-80033847	20040915
	JP 2007505901	T	20070315	JP 2006-526855	20040915
	RU 2353616	C2	20090427	RU 2006-112428	20040915
	NZ 545963	A	20090925	NZ 2004-545963	20040915
	MX 2006002724	A	20060606	MX 2006-2724	20060309
	KR 2006087569	A	20060802	KR 2006-705456	20060317
	ZA 2006002261	A	20070725	ZA 2006-2261	20060317
	NO 2006001660	A	20060411	NO 2006-1660	20060411
	IN 2006DN02107	A	20070713	IN 2006-DN2107	20060418
	IN 234227	A1	20090605		
	US 20070203129	A1	20070830	US 2007-572706	20070108
	IN 2009DN02359	A	20090522	IN 2009-DN2359	20090409
	IN 2009DN02360	A	20090522	IN 2009-DN2360	20090409
PRAI	SE 2003-2486	A	20030918		
	WO 2004-SE1335	W	20040915		
	IN 2006-DN2107	A3	20060418		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 142:316705; MARPAT 142:316705
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Y = CH, CF, N; R1 = H, alkyl; R2 = (un)substituted Ph, 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms; G1 = Ph, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms; each R5 = independently H, halo, CN, alkoxy, NO2, etc.; n = 1-3; R4 = H, (un)substituted alkyl; L = a

bond, O, SO, SO2, S, NH, etc.; G2 = (un)substituted monocyclyl, bicyclyl; and their optical isomers, racemates, tautomers, and pharmaceutically acceptable salts] were prepared as human neutrophil elastase (HNE) inhibitors for treating inflammation. Thus, acylation of 4-methylsulfonylbenzylamine•HCl with 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3- carboxylic acid (preparation given), iodination, and Pd-cross coupling of the iodide with phenylboronic acid gave pyridone II. Selected I gave IC50 values for inhibition of HNE activity of less than 30 μM.

IT 848141-11-7P, 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-[[5-(methylsulfonyl)pyridin-2-yl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 848141-15-1P, 5-(3,5-Dimethylisoxazol-4-yl)-6-methyl-N-[[5-(methylsulfonyl)pyridin-2-yl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-pyridones as human neutrophil elastase inhibitors and their use for treating inflammation)

RN 848141-11-7 CAPLUS

CN 3-Pyridinecarboxamide, 1,2-dihydro-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-[[5-(methylsulfonyl)-2-pyridinyl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 848141-15-1 CAPLUS

CN 3-Pyridinecarboxamide, 5-(3,5-dimethyl-4-isoxazolyl)-1,2-dihydro-6-methyl-N-[[5-(methylsulfonyl)-2-pyridinyl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



```
OSC.G   7     THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log y
STN INTERNATIONAL LOGOFF AT 07:55:36 ON 09 JUL 2010
```